GB2456434A - Buprenorphine-containing non-pressurised spray composition for transmucosal administration - Google Patents

Buprenorphine-containing non-pressurised spray composition for transmucosal administration Download PDF

Info

Publication number
GB2456434A
GB2456434A GB0905120A GB0905120A GB2456434A GB 2456434 A GB2456434 A GB 2456434A GB 0905120 A GB0905120 A GB 0905120A GB 0905120 A GB0905120 A GB 0905120A GB 2456434 A GB2456434 A GB 2456434A
Authority
GB
United Kingdom
Prior art keywords
buprenorphine
spray composition
containing non
transmucosal administration
pressurised spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0905120A
Other versions
GB0905120D0 (en
Inventor
Clive Booles
Padriac O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasol Ltd
Original Assignee
Pharmasol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Ltd filed Critical Pharmasol Ltd
Publication of GB0905120D0 publication Critical patent/GB0905120D0/en
Publication of GB2456434A publication Critical patent/GB2456434A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided according to the invention a non-pressurised pharmaceutical liquid solution spray composition comprising: (i) buprenorphine; and 5 (ii) a solvent comprising ethanol which composition is substantially free of chloride.
GB0905120A 2006-10-18 2009-03-25 Buprenorphine-containing non-pressurised spray composition for transmucosal administration Withdrawn GB2456434A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0620661.9A GB0620661D0 (en) 2006-10-18 2006-10-18 Novel compounds
PCT/GB2007/050639 WO2008047163A1 (en) 2006-10-18 2007-10-17 Buprenorphine-containing non-pressurised spray composition for transmucosal administration

Publications (2)

Publication Number Publication Date
GB0905120D0 GB0905120D0 (en) 2009-05-06
GB2456434A true GB2456434A (en) 2009-07-22

Family

ID=37507923

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0620661.9A Ceased GB0620661D0 (en) 2006-10-18 2006-10-18 Novel compounds
GB0905120A Withdrawn GB2456434A (en) 2006-10-18 2009-03-25 Buprenorphine-containing non-pressurised spray composition for transmucosal administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0620661.9A Ceased GB0620661D0 (en) 2006-10-18 2006-10-18 Novel compounds

Country Status (8)

Country Link
EP (1) EP2081574A1 (en)
CN (1) CN101573116A (en)
AU (1) AU2007311621A1 (en)
CA (1) CA2666581A1 (en)
GB (2) GB0620661D0 (en)
IL (1) IL197908A0 (en)
WO (1) WO2008047163A1 (en)
ZA (1) ZA200902123B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2577390T3 (en) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Transmucosal administration devices with greater uptake
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
WO2010072398A2 (en) * 2008-12-22 2010-07-01 Boehringer Ingelheim Limited Veterinary formulations
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2483579A (en) * 2010-06-30 2012-03-14 Londonpharma Ltd Sublingual formulations comprising methadone and ethanol for use in reducing pain
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EP2793870A4 (en) * 2011-12-21 2016-02-17 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA3003293A1 (en) 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097780A2 (en) * 2000-06-22 2001-12-27 Pharmasol Ltd Pharmaceutical compositions comprising an opioid analgesic
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US20040202617A1 (en) * 2001-05-24 2004-10-14 Alexza Molecular Delivery Corporation Delivery of opioids through an inhalation route
WO2005106350A2 (en) * 2004-04-23 2005-11-10 Philip Morris Usa Inc. Aerosol generators and methods for producing aerosols

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097780A2 (en) * 2000-06-22 2001-12-27 Pharmasol Ltd Pharmaceutical compositions comprising an opioid analgesic
US20040202617A1 (en) * 2001-05-24 2004-10-14 Alexza Molecular Delivery Corporation Delivery of opioids through an inhalation route
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
WO2005106350A2 (en) * 2004-04-23 2005-11-10 Philip Morris Usa Inc. Aerosol generators and methods for producing aerosols

Also Published As

Publication number Publication date
GB0905120D0 (en) 2009-05-06
GB0620661D0 (en) 2006-11-29
CN101573116A (en) 2009-11-04
WO2008047163A1 (en) 2008-04-24
CA2666581A1 (en) 2008-04-24
EP2081574A1 (en) 2009-07-29
IL197908A0 (en) 2009-12-24
AU2007311621A1 (en) 2008-04-24
ZA200902123B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
GB2456434A (en) Buprenorphine-containing non-pressurised spray composition for transmucosal administration
MX2009005462A (en) 7,8-saturated-4,5-epoxy-morphinanium analogs.
TW200833326A (en) Chemical compounds 572
WO2007130780A3 (en) Benzimidazole modulators of vr1
MX2009007104A (en) Substituted oxindole derivatives and their use as vasopressin receptor ligands.
MX2009005461A (en) N-oxides of 4,5-epoxy-morphinanium analogs.
WO2008005565A3 (en) Antiviral phosphinate compounds
MX2009013830A (en) Antiviral compounds.
MX2010014234A (en) Pyrazole compounds 436.
UA98494C2 (en) Antiviral compounds
HK1132742A1 (en) Substituted oxindole derivative and its use as a vasopressin receptor modulator
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY153976A (en) Lh liquid formulations
SV2006002274A (en) DERIVATIVES OF 2-AMIDO-4-PHENYLTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
TW200745122A (en) New compounds I
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
SG158091A1 (en) Imidazoazepinone compounds
PT1987063E (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2007103869A3 (en) Liquid and semi-solid pharmaceutical formulations and processes
WO2009130422A3 (en) N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
WO2007103867A3 (en) Tablet formulations and processes
IL191670A0 (en) Compounds for the inhibition of apoptosis
EP2101742B8 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
MX2014003334A (en) New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments.
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)